Sells LOQTORZI, a treatment for nasopharyngeal cancer, to hospitals and clinics, and develops antibody candidates for other cancers.
10-K for FY2025, filed Mar 9, 2026We are a fully integrated commercial-stage innovative oncology company with an approved next-generation programmed death receptor-1…View ↗
On October 27, 2023, we announced that LOQTORZI was approved by the U.S. Food and Drug Administration (“FDA”) in combination with cisplatin…View ↗
The Company sells to wholesalers and distributors, (collectively, “Customers”). The Customers then resell to hospitals and clinics…View ↗
Coherus sells LOQTORZI to wholesalers and distributors for resale to hospitals and clinics; payment typically follows shipment.
10-K for FY2025, filed Mar 9, 2026The Company sells to wholesalers and distributors, (collectively, “Customers”). The Customers then resell to hospitals and clinics…View ↗
10-K for FY2025, filed Mar 9, 2026
FY2025 revenue by product or service ↗$42.2M
10-K for FY2025, filed Mar 9, 2026
$42.2M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Toripalimab
Sold outright
10-K for FY2025, filed Mar 9, 2026 |
97% |
Toripalimab, FY2025
$40.8M Sources
|
Sold outright |
|
Other revenue
|
3.2%
FY2022: 0.1%
|
Other revenue, FY2025
$1.3M Sources
|
Coherus sells LOQTORZI to wholesale distributors, which resell it to hospitals and clinics; group purchasing organizations and commercial or government payers are involved in discounts and reimbursement.
10-K for FY2025, filed Mar 9, 2026
10-K for FY2025, filed Mar 9, 2026
Year Ended December 31, 2025 2024 McKesson Corporation 43 % 43 % Cencora, Inc. 36 % 43 % Cardinal Health, Inc. 20 %…View ↗
Yes. Its net income in FY2025 was larger than its revenue.
10-Q for Q3 FY2026, filed Nov 9, 2026
−$39.3MView ↗
10-Q for Q3 FY2026, filed Nov 9, 2026
Open tableView ↗
8-K, filed Jun 15, 2026
On June 12, 2026, the Audit Committee (the “Audit Committee”) of the Board of Directors of Coherus Oncology, Inc. (the “Company”) dismissed…View ↗
Shrinking. Revenue fell 87% in 4 years, from $326.6M in FY2021 to $42.2M in FY2025, about 40% a year.
Shift to oncology focus
The older report described biosimilars alongside oncology development; the latest describes a business focused on LOQTORZI and immuno-oncology candidates after biosimilar divestitures.
10-K for FY2022, filed Mar 6, 2023 10-K for FY2025, filed Mar 9, 2026We are a fully integrated commercial-stage innovative oncology company with an approved next-generation programmed death receptor-1…View ↗
Competes with Merck, Bristol-Myers Squibb, Genentech, AstraZeneca, EMD Serono, Pfizer, Regeneron Pharmaceuticals, GlaxoSmithKline, BeiGene, Elevar Therapeutics, Jiangsu Hengrui Pharmaceuticals, Akeso, Gilead Sciences, Jounce Therapeutics, Shionogi, AbbVie, Bayer, F. Hoffmann-La Roche, Amgen, and LaNova Medicines
10-K for FY2025, filed Mar 9, 2026LOQTORZI faces a competitive market in the United States where a number of anti-PD-1 or PD-L1 antibody drugs have been approved by the FDA…View ↗
Loading...